AR226_ 3277 459 ~ Effects on the Development of Caenorhabditiselegans in a Water-Sediment System pn ----ty Sa--or--es_at hoe cri nmin Ontdbine .

rraJin-ni/iWH Sc^pe- --------'I ----t-.

Biotransformation of the ^C-labeled Fluorotelo Telomer B Alcohol* Wang N.1.

HAZLEZON LABORATORIES AAIERICA, INC. 3301 KINSMAN BLVD.

,)'HAZLrm%CN LABCNDMMRIEB AA/ERICA, INC. 3301KINSMAN BLVD. p.o.BOX 45 MADISON, WISCONSIN 53707 Chemical& BioMedicalSciencesDivision PHONE (608)241-4471 TLX 703966HAZRAL MDS UD FINAL REPORT JUL, JANINE GLEASON MINNESOTA MINING & MANUFACTURING TOXICOLOGY SERVICES ST.

3M EnvirOnmental Laboratory Pmjeci No. 05-0210 Interim Report #5: Analysis of West MorganlEast Lawrence Municipal Water Samples Study Title ANALYSIS OF PERFLUOROBUTANESULFONATE(PFBS), PERFLUOROHEXANESULFONATE (PFHS), AND PERFLUOROOCTANESULFONATE(PFOS) IN WATER, SOIL, SEDIMENT, FISH, CLAMS, VEGETATION, SMALL MAMMALIVER AND SMALL MAMMALSERUM USING LC/MS/MS FOR THE 3M DECATURMONITORINGPROGRAM Data Requirement EPA TSCA Good Laboratory Practice Standards 40 CFR 792 Author Michelle D.

Covance Studies AR226-0/68 The attached report summarizes the results from the assessment of `mitochondrial bioenergetics of hepatic mitochondria isolated from rats treated for 3 weeks with one of 4 doses (plus control) of dietary FC10.

@ HAZLER TONr wormTsRseTnceRI TIRSuT a M as n xEST COPY AVAILABLE PanJo-- E4EECCEIVS> JAN271988 RHTbOGaEooRcnhGd.TaalPaEFRRIKNRIIuNNISGCE&sMANUFACTURING COMPANY Noy,riaMonEv SenMPLERIFGER: 7090576 SALE EHTERED?

= EPAlPuRt Nene brgenizechon lp <S < upe- D n Oe BbBuc Tadbin Suma lose Allie Codey Rin s Cell Diifont EFA/EETD EP [ced eva [ced Eek(cco Cwheoe UnPoere nogle Mugs Ha KDeavkide,MoArtrele ~ ke Lac eEPon/(cZcsd E PERG pA Ep [RAD RAS EO fei V dette fodes Chale Aur New Parse Lh pA bp ex: kaonrny D[ orrie zn Hennnnce AY 6.

7 Gchaa7r2sa7hu2n0t00 01:39 PM TT o E geraldmaknednencec/yD@OU/SUASdEuPpAo/nUtSoGmEPA, pateLnei@epa gov Subject Request for change in submission da for PFOR exposure infomation GTTehraarnyk.s for your EMaiyw2i, t20c0o0rtleitteoirfsswtihhioecnrheb,qyuaeMmsaotynegd26iotnohffeorrtmotahxtiiinogcns,oinnnfooatremmsmattoihnoanituoDmnuPPPoFFnOOtAS.

AR QAG _ 0653 PFOS Pharmacokinetic - 2 000169 _ .

wna E ee m ri [3TA %RFB SPoS suo UDSr.EOPscAa/rOPHeRmTaInCdCeDz(7405) 22 B Somtoamoe m0coD r troG meo onTAeHornte TE E emtRts o rm eeeE t aA nEe Es me n TISE E Himntm sptme eterE mmCTn ep eI m eneSere Tee R TE oE m Tieomtem e es eoLI ottrem LS DsrmEemEoteS crt e m ertyetisntcte le rUOraS.geSOsPcAaOrPtPemTaInCtCeDr (7409 Pleascontact medirty 65173-6374 ouhav sy usinein is por Bogus, AlsO Aegon SEDWpaiielvclioiioaarnlmmyeAM.saWle,lppFneelyrt,is,kPheS.Dsu.eGyo& Regisoy ATs SSMtClomeMrNBlSdgi2e36-13:10

Northwest Biossalyt0ial 226-172 9 ReSgtoryt NNoo,,NNWWBBRS0O0L..009615 Quantitative Determination of PFOS and Related Compounds in Human Serum and Plasma by LC/MS/MS Sample Analysis Report for Protocol EPL0012 NortAhwDeisvtisBiioonanoaflNytWicTalI(ncN.WB) Sal1t12L1akEeasCtit3y9,00UTSo8u4t1h24 PREPARED FOR: 3M Company Epidemiology, Medical Department 2203W-05 StPaul, MN 55144 2= EEZR on = ue 2 AUTHOR: Oinie J Dbl Connie O.

StudyTide FC-143:TWoYEARORAL TOXIITY-ONCOSGTUEDNYICNIRATTYS PEER RevoFiOveanwes Authors Peter C.

AR226-2057 C-B PERSONAL AIR MOUTOMN8 3ATA NASHIN6TON WORKS - BTO COPOPTMERS ORSA <A88) (AEa.